论文部分内容阅读
目的:探讨失代偿期乙型肝炎(以下简称乙肝)肝硬化患者不同病毒学应答状态对生存率、肝癌患病率的影响。方法:抽取2017年3月至2019年9月周口市中心医院收治的失代偿期乙肝肝硬化患者142例，根据抗病毒治疗过程中乙肝病毒脱氧核糖核酸(HBV-DNA)的持续可测性，将持续病毒学应答的90例患者作为A组，非持续病毒学应答的52例患者作为B组。比较两组患者以及应用不同药物治疗患者间的1年肝癌累积发生率与无肝移植生存率。结果:A组患者1年肝癌累积发生率为1.11%(1/90)，低于B组的7.67%(4/52)，差异有统计学意义(n P<0.05)。A组患者的1年无肝移植生存率为98.89%(89/90)，高于B组的92.31%(48/52)，差异有统计学意义(n P0.05)。n 结论:失代偿期乙肝致肝硬化患者应用抗病毒治疗可改善疾病预后，不受药物差异的明显影响，持续病毒学应答可使患者肝癌患病率降低，提高患者的无肝移植生存率。“,”Objective:To investigate the influence of different virological response states on survival rate and incidence of liver cancer in patients with decompensated hepatitis B virus (HBV) cirrhosis.Methods:A total of 142 patients with decompensated hepatitis B cirrhosis in Zhoukou Central Hospital from March 2017 to September 2019 were selected. According to the continuous measurability of HBV-DNA during the treatment of antiviral therapy, 90 patients with persistent virological response were allocated into group A, and 52 patients without persistent virological response were allocated into group B. The one-year cumulative incidence of liver cancer and the survival rate without liver transplantation were compared between the two groups, and the one-year cumulative incidence of liver cancer and survival without liver transplantation were compared among patients treated with different drugs.Results:The one-year cumulative incidence of liver cancer in group A was 1.11%(1/90), which was lower than that in group B (7.67%, 4/52), and the difference was statistically significant (n P<0.05). The one-year non liver transplantation survival rate in group A was 98.89%(89/90), which was higher than that in group B (92.31%, 48/52), and the difference was statistically significant (n P0.05).n Conclusions:Antiviral therapy can improve the prognosis of patients with decompensated hepatitis B cirrhosis, which can not be affected by the drug difference. The continuous virological response can reduce the incidence of liver cancer, and improve the survival rate of patients without liver transplantation.